FPR2

Summary

FPR2 (formyl peptide receptor 2, HGNC:3827) is a protein-coding gene on chromosome 19q13.41, encoding N-formyl peptide receptor 2 (P25090). Pattern recognition G protein-coupled receptor (GPCR) that recognizes peptides with N-terminal formyl methionine, which are derived from invading pathogens or host mitochondria as pathogen or damage-associated molecular patterns (PAMPs and DAMPs).

Enables amyloid-beta binding activity; scavenger receptor binding activity; and signaling receptor activity. Involved in several processes, including cellular response to amyloid-beta; positive regulation of ERK1 and ERK2 cascade; and regulation of defense response. Located in cytoplasm and plasma membrane.

Source: NCBI Gene 2358 — RefSeq curated summary.

At a glance

• GWAS associations: 4
• Clinical variants (ClinVar): 48 total
• Druggable target: yes — 4 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_001005738

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:3827
Approved symbol	FPR2
Name	formyl peptide receptor 2
Location	19q13.41
Locus type	gene with protein product
Status	Approved
Aliases	LXA4R, HM63, FPRH2, FMLPX, FPR2A, FMLP-R-II, ALXR, ALX
Ensembl gene	ENSG00000171049
Ensembl biotype	protein_coding
OMIM	136538
Entrez	2358

Gene structure

Transcript identifiers

Ensembl transcripts: 6 — 6 protein_coding

ENST00000340023, ENST00000598776, ENST00000598953, ENST00000599326, ENST00000600258, ENST00000600722

RefSeq mRNA: 2 — MANE Select: NM_001005738 NM_001005738, NM_001462

CCDS: CCDS12840

Canonical transcript exons

ENST00000340023 — 2 exons

Exon	Start	End
ENSE00003127886	51761180	51761230
ENSE00003447537	51768645	51770531

Expression profiles

Bgee: expression breadth ubiquitous, 159 present calls, max score 95.55.

FANTOM5 (CAGE): breadth broad, TPM avg 8.0372 / max 1741.5119, expressed in 282 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
177254	6.0474	225
177246	0.4681	51
177251	0.3439	92
177248	0.2738	38
177255	0.2388	56
177250	0.2301	88
177253	0.1836	60
208914	0.0713	28
177252	0.0639	43
177256	0.0583	13

Top tissues by expression

284 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
blood	UBERON:0000178	95.55	gold quality
monocyte	CL:0000576	95.13	gold quality
leukocyte	CL:0000738	94.56	gold quality
mononuclear cell	CL:0000842	94.55	gold quality
granulocyte	CL:0000094	89.88	gold quality
bone marrow	UBERON:0002371	87.57	gold quality
Brodmann (1909) area 10	UBERON:0013541	86.00	silver quality
bone marrow cell	CL:0002092	85.63	gold quality
right lung	UBERON:0002167	83.22	gold quality
spleen	UBERON:0002106	83.00	gold quality
vermiform appendix	UBERON:0001154	80.83	gold quality
periodontal ligament	UBERON:0008266	78.93	gold quality
upper lobe of left lung	UBERON:0008952	78.92	gold quality
frontal pole	UBERON:0002795	77.76	gold quality
paraflocculus	UBERON:0005351	77.45	gold quality
upper lobe of lung	UBERON:0008948	77.26	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	77.22	gold quality
middle frontal gyrus	UBERON:0002702	76.91	silver quality
caecum	UBERON:0001153	74.14	gold quality
lung	UBERON:0002048	71.40	gold quality
gall bladder	UBERON:0002110	71.33	gold quality
endometrium epithelium	UBERON:0004811	70.59	gold quality
trabecular bone tissue	UBERON:0002483	68.04	gold quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	66.89	gold quality
smooth muscle tissue	UBERON:0001135	66.61	gold quality
palpebral conjunctiva	UBERON:0001812	65.63	gold quality
left uterine tube	UBERON:0001303	65.62	gold quality
omental fat pad	UBERON:0010414	64.71	gold quality
peritoneum	UBERON:0002358	64.65	gold quality
adipose tissue of abdominal region	UBERON:0007808	63.99	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 2.

Experiment	Marker?	Max mean expression
E-MTAB-9801	yes	6.08
E-ANND-3	yes	4.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): BHLHA15, CREBZF, TAL1

miRNA regulators (miRDB)

47 targeting FPR2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-3185	99.99	68.12	1959
HSA-MIR-433-3P	99.98	69.37	1203
HSA-MIR-4803	99.98	71.99	3117
HSA-MIR-302C-5P	99.97	72.56	3642
HSA-MIR-6755-5P	99.95	65.59	464
HSA-MIR-144-3P	99.94	73.98	2698
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-9902	99.89	69.15	2250
HSA-MIR-548AZ-5P	99.83	69.94	3230
HSA-MIR-548T-5P	99.83	69.91	3220
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-548AV-5P	99.60	70.84	2107
HSA-MIR-548K	99.60	70.84	2107
HSA-MIR-885-5P	99.59	68.59	879
HSA-MIR-451B	99.55	68.28	1380
HSA-MIR-3120-3P	99.54	70.28	2669
HSA-MIR-3609	99.52	69.89	2587
HSA-MIR-548AH-5P	99.52	69.73	2626
HSA-MIR-543	99.52	69.03	2595
HSA-MIR-7159-3P	99.51	70.17	1920
HSA-MIR-4441	99.49	66.56	3216
HSA-MIR-8054	99.48	70.81	2084
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-3140-5P	99.39	69.04	1136
HSA-MIR-4427	99.34	70.33	1854
HSA-MIR-580-5P	99.28	70.94	1776
HSA-MIR-1264	99.25	66.81	1317
HSA-MIR-122B-3P	99.21	68.90	1333

Literature-anchored findings (GeneRIF, showing 40)

• chemoattractant Trp-Lys-Tyr-Met-Val-D-Met activates eosinophils through the formyl peptide receptor and one of its homologues, formyl peptide receptor-like 1 (PMID:12377951)
• results indicate that the cytokine-like property of serum amyloid A is manifested through activation of the Gi-coupled formyl peptide receptor-like 1(FPRL1/LXA4R) (PMID:12393391)
• investigated the direct effect of LXA4 as well as the effect on agonist-induced biological responses using transfected HL-60 cells expressing FPR, FPRL1 or FPRL2 (PMID:12410796)
• LXA(4) generated in or near the paracellular space via neutrophil-epithelial interactions can rapidly act on epithelial LXA(4)receptor to downregulate epithelial promotion of intestinal inflammation. (PMID:12456400)
• Modulation of neutrophil FPRL1 by distinct peptide ligands activates a spectrum of cellular signaling events, including intracellular calcium concentration increase, phosphoinositide 3-kinase, extracellular signal-regulated kinase, and Akt activation. (PMID:14662886)
• an annexin 1 peptide can activate FPR, FPRL1, and FPRL2; results indicate that annexin 1 participates in regulating leukocyte emigration into inflamed tissue by activating and desensitizing different receptors of the FPR family. (PMID:15187149)
• The up-regulation of the A-SAA and FPRL1 genes in inflamed synovial tissue suggests an important role in the pathophysiology of inflammatory arthritis (PMID:15188355)
• ligand-bound FPRL1 undergoes primarily clathrin-mediated and dynamin-dependent endocytosis (PMID:15224191)
• Results show that humanin (HN) acts as a ligand for formyl peptide receptor-like 1 (FPRL1) and 2 (FPRL2). (PMID:15465011)
• FPR and FPRL1, use distinct signaling pathways in activation of human neutrophils (PMID:15625007)
• results showed that multiple domains in FPRL1 are involved in the receptor response to chemotactic agonists with the sixth transmembrane domain and the third extracellular loop playing a prominent role (PMID:15670157)
• serum amyloid A plays a role in the modulation of inflammatory and immune responses via FPRL1, by inducing matrix-metalloproteinase-9 upregulation (PMID:15809093)
• cells transfected with FPRL1 gene exhibited markedly reduced tumorigenicity in syngeneic mice (PMID:15829413)
• FPRL1 is a pituitary adenylate cyclase activating polypeptide (PACAP) 27-specific receptor. (PMID:16493055)
• In view of the wide range of endogenous ligands known to interact with FPRL-1, including the anti-inflammatory protein annexin-A1, we speculate that the novel effect here described may impact on the clinical immunosuppressive (PMID:16973129)
• binding of SAA to FPRL1 may contribute to the destruction of bone and cartilage via the promotion of synoviocyte hyperplasia and angiogenesis (PMID:17015746)
• Analysis of in vitro expression of lipoxin A(4) receptor (ALX) on human neutrophils and the in vivo anti-inflammatory effect of glucocorticoids. (PMID:17184966)
• The N-formyl peptide receptors present in MSCs may play an important role in signaling stem cell adhesion, migration, and homing to injured and inflamed tissue for repair. (PMID:17234990)
• association of the PDGFRbeta with lipid raft microdomains renders it susceptible to LXA(4)-mediated dephosphorylation by possible reactivation of oxidatively inactivated SHP-2. (PMID:17403678)
• Exocytosis of FPRL1 results in down-regulation of cytoplasmic FRPL1 in patients with pyoderma. (PMID:17460114)
• Both intra- and extracellular Ca2+ play a role in controlling pro-inflammatory functions stimulated by PACAP which acts through a VPAC-1, FPRL1/Galphai/PI3K/ERK pathway and a VPAC-1/Galphas/PKA/p38 pathway to fully activate monocytes (PMID:17651798)
• To specifically inhibit the FPRL1 response the antagonist WRW(4) should be used. (PMID:17687636)
• Piroxicam inhibits the neutrophil responses triggered through formyl peptide receptor, but not through formyl peptide receptor like 1 and this inhibition is due to a reduced binding of the activating ligand to its cell surface receptor. (PMID:17692291)
• FPRL-1 is capable of activating nuclear factor-kappa B (NF-kappaB) signaling through inhibitor-kappa B kinase (IKK) phosphorylation in human astrocytoma or Chinese hamster ovary cells. (PMID:17727628)
• level of LXA4 in synovial fluid and lipoxin A4 receptor expression in synovial tissues obtained from patients with rheumatoid arthritis and osteoarthritis (PMID:17918787)
• Proinflammatory effect of VIP is mediated via the specific G protein-coupled receptor VIP/pituitary adenylate cyclase-activating protein (VPAC1) receptor as well as via FPRL1. (PMID:18174366)
• Our results indicate that severe asthma is characterized by decreased airway LXA4 levels and luekocyte AKX receptor availability. (PMID:18583575)
• FPRL1 is a potent mediator in the activation of CRAC channels (PMID:18652801)
• The chemokine FPRL1 plays a role in the production of chemokine CCL2 by serum amyloid A. (PMID:18768891)
• Data show that MMK-1 is a member of a group of FPR2 ligands that activate the neutrophil superoxide-generating NADPH-oxidase. (PMID:19282028)
• FPRL1-induced chemotactic migration and IL-1 beta production from human phagocytes was ihibited by lysophosphatidylglycerol. (PMID:19381066)
• These results suggest that CCR3 may be used as a surrogate co-receptor by subtype B while FPRL1 may be used as a surrogate co-receptor by subtypes A and C HIV-1. (PMID:19553323)
• LXA(4) does not act through FPR2 in neutrophils. (PMID:19751275)
• ECRG2 regulates invasion/migration partly through ECM degradation and uPA/uPAR/FPRL1 pathway (PMID:19796867)
• both LxA4 and a chemotactic lipid leishmania chemotactic factor released by the parasite leishmania increased infectivity of this pathogen in an lipoxin A4 receptor dependent fashion (PMID:19811292)
• All tested samples of human natural killer (NK) cells express FPR2; activation of FPR2 elicits cytolytic activity and chemotactic migration of NK cells. (PMID:19843937)
• The results indicate that SAA stimulates FPR2-mediated activation of p38 MAPK and JNK, which are independent of a pertussis toxin-sensitive G-protein and are essential for SAA-induced CCL2 production. (PMID:20177146)
• These data demonstrate that the human formyl peptide receptor 2 (FPR2/ALX) senses phenol-soluble modulins at nanomolar concentrations and initiates proinflammatory neutrophil responses to community acquired MRSA. (PMID:20542250)
• promoter polymorphism is associated with chronic urticaria in a Korean population (PMID:20642210)
• These observations suggest a novel signaling role for ANXA1 in mitogen-activated proliferation of breast tumor epithelial cells that is mediated via activation of FPR1 and FPR2. (PMID:20930115)

Cross-species orthologs

11 orthologs

Organism	Symbol	Gene ID
mus_musculus	Fpr-rs4	ENSMUSG00000048062
mus_musculus	Fpr2	ENSMUSG00000052270
mus_musculus	Fpr-rs3	ENSMUSG00000060701
mus_musculus	Fpr-rs6	ENSMUSG00000071275
mus_musculus	Fpr-rs7	ENSMUSG00000071276
mus_musculus	Fpr3	ENSMUSG00000079700
rattus_norvegicus	Fpr3	ENSRNOG00000031331
rattus_norvegicus	Fpr2	ENSRNOG00000042605
rattus_norvegicus	Fpr2l2	ENSRNOG00000043056
rattus_norvegicus	Fpr2l1	ENSRNOG00000045732
rattus_norvegicus	Fpr2l2	ENSRNOG00000079547

Paralogs (8): C5AR2 (ENSG00000134830), GPR32 (ENSG00000142511), FPR1 (ENSG00000171051), C3AR1 (ENSG00000171860), CMKLR1 (ENSG00000174600), FPR3 (ENSG00000187474), C5AR1 (ENSG00000197405), GPR33 (ENSG00000214943)

Protein

Protein identifiers

N-formyl peptide receptor 2 — P25090 (reviewed: P25090)

Alternative names: FMLP-related receptor I, Formyl peptide receptor-like 1, HM63, Lipoxin A4 receptor, RFP

All UniProt accessions (4): P25090, M0QXD3, M0QZ89, M0R222

UniProt curated annotations — full annotation on UniProt →

Function. Pattern recognition G protein-coupled receptor (GPCR) that recognizes peptides with N-terminal formyl methionine, which are derived from invading pathogens or host mitochondria as pathogen or damage-associated molecular patterns (PAMPs and DAMPs). Preferentially recognizes longer peptides or peptides with specific sequences such as the phenol-soluble modulin (PSM) family of formylated peptide toxins produced by Staphylococcus aureus. Ligand binding causes a conformation change that triggers signaling via G(i)/GNAI1 inhibiting adenylate cyclase activity, leading to decreased intracellular cAMP levels. In addition, can recognize a variety of chemically distinct endogenous ligands including proteins and lipids besides formylpeptides and thereby plays multiple roles in inflammation. Acts as a receptor for the chemokine-like protein FAM19A5, mediating FAM19A5-stimulated macrophage chemotaxis and the inhibitory effect on TNFSF11/RANKL-induced osteoclast differentiation. Acts also as a ceramide membrane receptor, and long-chain ceramides (C14 to C20) binding induces conformational changes that inhibits diet-induced adipose thermogenesis. Participates in neuroprotection via interaction with humanin/MT-RNR2 and Amyloid-beta protein 42, product of APP. Differential signaling is also defined by receptor oligomerization state. Binding of ANXA1 to FPR2 homodimer elicits activation of p38 MAPKinase pathway leading to HSPB1/HSP27 phosphorylation and IL10 production in monocytes. Whereas agonistic activation of FPR1:FPR2 heterodimers signals a proapoptotic JNK pathway in neutrophils.

Subunit / interactions. Homodimer; the homodimerization is potentiated in response to the anti-inflammatory agonist ANXA1 and inhibited upon binding of pro-inflammatory agonist serum amyloid A. Heterodimer with FPR1; the heterodimerization with FPR1 is potentiated in response to anti-inflammatory agonists such as lipoxin A4, ANXA1 and Ac2-26 ANXA1 peptide. Forms a complex with heterotrimeric G(i) protein composed of GNAI1, GNB1 and GNG2 subunits. Interacts with amyloid-beta protein 42, product of APP; the interaction takes place at the cell surface and the complex is then rapidly internalized. Interacts with S1PR4. Interacts with GNAI1. Interacts with humanin/MT-RNR2. Interacts with GNAI2. (Microbial infection) Interacts with Staphylococcus aureus protein SSL13; this interaction leads to the activation of neutrophils.

Subcellular location. Cell membrane.

Tissue specificity. Detected in lung, bone marrow, neutrophils, spleen and testis.

Similarity. Belongs to the G-protein coupled receptor 1 family.

RefSeq proteins (2): NP_001005738, NP_001453 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR000826	Formyl_rcpt-rel	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (51 total): helix 18, topological domain 8, transmembrane region 7, strand 6, binding site 3, turn 3, chain 1, region of interest 1, compositionally biased region 1, glycosylation site 1, disulfide bond 1, sequence conflict 1

Structure

Experimental structures (PDB)

13 structures.

PDB	Method	Resolution (Å)
8ZBW	ELECTRON MICROSCOPY	2.58
6LW5	X-RAY DIFFRACTION	2.8
7WVX	ELECTRON MICROSCOPY	2.8
7T6U	ELECTRON MICROSCOPY	2.9
7WVV	ELECTRON MICROSCOPY	2.9
7T6S	ELECTRON MICROSCOPY	3
7WVY	ELECTRON MICROSCOPY	3
7T6V	ELECTRON MICROSCOPY	3.1
7WVW	ELECTRON MICROSCOPY	3.1
6OMM	ELECTRON MICROSCOPY	3.17
8Y62	ELECTRON MICROSCOPY	3.2
8Y63	ELECTRON MICROSCOPY	3.2
9JHJ	ELECTRON MICROSCOPY	3.2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P25090-F1	84.87	0.66

Antibody-complex structures (SAbDab): 6 — 6OMM, 7T6S, 7T6U, 7T6V, 8Y62, 9JHJ

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 106; 201; 205

Disulfide bonds (1): 98–176

Glycosylation sites (1): 4

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-416476	G alpha (q) signalling events
R-HSA-418594	G alpha (i) signalling events
R-HSA-444473	Formyl peptide receptors bind formyl peptides and many other ligands
R-HSA-6798695	Neutrophil degranulation

MSigDB gene sets: 346 (showing top): GSE45365_NK_CELL_VS_CD11B_DC_DN, GOBP_RESPONSE_TO_NITROGEN_COMPOUND, GOBP_NEGATIVE_REGULATION_OF_NEURON_APOPTOTIC_PROCESS, REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_POSITIVE_REGULATION_OF_ENDOCYTOSIS, GOBP_MYELOID_LEUKOCYTE_MIGRATION, MORF_MSH3, GOBP_CELL_CHEMOTAXIS, MODULE_255, GOBP_INFLAMMATORY_RESPONSE, GOCC_SECRETORY_GRANULE, MODULE_45, MODULE_64, MORF_BRCA1, GOBP_REGULATION_OF_SUPEROXIDE_ANION_GENERATION

GO Biological Process (29): microglial cell activation (GO:0001774), complement receptor mediated signaling pathway (GO:0002430), immune response-regulating cell surface receptor signaling pathway (GO:0002768), receptor-mediated endocytosis (GO:0006898), chemotaxis (GO:0006935), inflammatory response (GO:0006954), cell adhesion (GO:0007155), cell surface receptor signaling pathway (GO:0007166), G protein-coupled receptor signaling pathway (GO:0007186), adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway (GO:0007193), phospholipase C-activating G protein-coupled receptor signaling pathway (GO:0007200), positive regulation of cytosolic calcium ion concentration (GO:0007204), calcium-mediated signaling (GO:0019722), positive regulation of superoxide anion generation (GO:0032930), defense response to bacterium (GO:0042742), negative regulation of neuron apoptotic process (GO:0043524), positive regulation of innate immune response (GO:0045089), astrocyte activation (GO:0048143), negative regulation of inflammatory response (GO:0050728), positive regulation of phagocytosis (GO:0050766), positive chemotaxis (GO:0050918), positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction (GO:0051897), positive regulation of ERK1 and ERK2 cascade (GO:0070374), positive regulation of monocyte chemotaxis (GO:0090026), dentinogenesis (GO:0097187), cellular response to amyloid-beta (GO:1904646), cell communication (GO:0007154), signal transduction (GO:0007165), signaling (GO:0023052)

GO Molecular Function (9): amyloid-beta binding (GO:0001540), complement receptor activity (GO:0004875), G protein-coupled receptor activity (GO:0004930), N-formyl peptide receptor activity (GO:0004982), scavenger receptor binding (GO:0005124), signaling receptor activity (GO:0038023), cargo receptor activity (GO:0038024), RAGE receptor binding (GO:0050786), protein binding (GO:0005515)

GO Cellular Component (6): cytoplasm (GO:0005737), plasma membrane (GO:0005886), membrane (GO:0016020), specific granule membrane (GO:0035579), tertiary granule membrane (GO:0070821), ficolin-1-rich granule membrane (GO:0101003)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
GPCR downstream signalling	2
Peptide ligand-binding receptors	1
Innate Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
secretory granule membrane	3
glial cell activation	2
defense response	2
signal transduction	2
G protein-coupled receptor signaling pathway	2
transmembrane signaling receptor activity	2
signaling receptor binding	2
cellular anatomical structure	2
tertiary granule	2
leukocyte activation involved in inflammatory response	1
macrophage activation	1
immune response-activating cell surface receptor signaling pathway	1
immune response-regulating signaling pathway	1
cell surface receptor signaling pathway	1
endocytosis	1
response to chemical	1
taxis	1
cellular process	1
G protein-coupled receptor activity	1
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	1
adenylate cyclase inhibitor activity	1
phospholipase C activator activity	1
regulation of biological quality	1
intracellular signaling cassette	1
regulation of superoxide anion generation	1
superoxide anion generation	1
positive regulation of reactive oxygen species metabolic process	1
response to bacterium	1
negative regulation of apoptotic process	1
regulation of neuron apoptotic process	1
neuron apoptotic process	1
positive regulation of response to biotic stimulus	1
positive regulation of defense response	1
positive regulation of response to external stimulus	1
innate immune response	1
regulation of innate immune response	1
positive regulation of immune response	1
astrocyte development	1
inflammatory response	1
negative regulation of defense response	1

Protein interactions and networks

STRING

1792 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FPR2	ANXA1	P04083	999
FPR2	CAMP	P49913	997
FPR2	HSH2D	Q96JZ2	845
FPR2	PLAUR	Q03405	790
FPR2	APP	P05067	759
FPR2	TRIM11	Q96F44	683
FPR2	SAA1	P02735	683
FPR2	PRNP	P04156	675
FPR2	A0A087WTN9	A0A087WTN9	672
FPR2	PLEKHF1	Q96S99	653
FPR2	ITGAM	P11215	623
FPR2	RARRES2	Q99969	622
FPR2	SCARB1	Q8WTV0	610
FPR2	CXCL1	P09341	602
FPR2	IL27RA	Q6UWB1	595

IntAct

23 interactions, top by confidence:

A	B	Type	Score
FPR2	ARL6IP5	psi-mi:“MI:0914”(association)	0.640
APOD	FPR2	psi-mi:“MI:0915”(physical association)	0.560
FPR2	FXYD6	psi-mi:“MI:0915”(physical association)	0.560
FPR2	LRRC25	psi-mi:“MI:0915”(physical association)	0.560
FPR2	SSMEM1	psi-mi:“MI:0915”(physical association)	0.560
APP	FPR2	psi-mi:“MI:0915”(physical association)	0.560
FPR2	RAMP1	psi-mi:“MI:0915”(physical association)	0.400
FPR2	RAMP2	psi-mi:“MI:0915”(physical association)	0.400
RAMP3	FPR2	psi-mi:“MI:0915”(physical association)	0.400
FPR2	GPR89A	psi-mi:“MI:0914”(association)	0.350
FPR2	SCAMP3	psi-mi:“MI:0914”(association)	0.350
FXYD6	FPR2	psi-mi:“MI:0915”(physical association)	0.000
FPR2	LRRC25	psi-mi:“MI:0915”(physical association)	0.000
FPR2	SSMEM1	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (197): FUNDC2 (Affinity Capture-MS), REEP6 (Affinity Capture-MS), ATP2B3 (Affinity Capture-MS), SLC38A9 (Affinity Capture-MS), FNDC3A (Affinity Capture-MS), SLC30A5 (Affinity Capture-MS), RRAGB (Affinity Capture-MS), ELOVL2 (Affinity Capture-MS), ATP2B4 (Affinity Capture-MS), DOLK (Affinity Capture-MS), ARL6IP1 (Affinity Capture-MS), RTN2 (Affinity Capture-MS), CERS5 (Affinity Capture-MS), TRIM4 (Affinity Capture-MS), CAMLG (Affinity Capture-MS)

ESM2 similar proteins: A4FUQ5, B9VR26, O08790, O35786, O70129, O75388, O88416, O88536, O88537, O97664, P0C7U4, P21462, P21730, P25089, P25090, P30992, P30993, P33766, P35343, P35407, P46090, P46091, P79175, P79176, P79177, P79178, P79188, P79189, P79190, P79191, P79234, P79235, P79236, P79237, P79240, P79241, P79242, P79243, P97468, P97520

Diamond homologs: A4FUQ5, B1PHQ8, B9VR26, O08565, O08790, O35210, O35786, O62747, O70129, O75388, O77590, O88416, O88536, O88537, O97571, O97664, P0C7U4, P0C7U5, P21462, P21730, P25025, P25089, P25090, P25095, P25104, P28646, P29089, P29754, P29755, P30555, P30556, P30872, P30873, P30937, P30992, P30993, P31391, P33766, P34976, P35373

SIGNOR signaling

5 interactions.

A	Effect	B	Mechanism
FPR2	“up-regulates activity”	GNAI3	binding
FPR2	“up-regulates activity”	GNA14	binding
WKYMVm	“up-regulates activity”	FPR2	“chemical activation”
ANXA1	“up-regulates activity”	FPR2	binding
CAMP	up-regulates	FPR2	binding

Disease & clinical

Clinical variants and AI predictions

ClinVar

48 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	42
Likely benign	3
Benign	2

Top pathogenic / likely-pathogenic (0)

SpliceAI

236 predictions. Top by Δscore:

Variant	Effect	Δscore
19:51761227:GCTG:G	donor_gain	0.9800
19:51763442:A:G	donor_gain	0.9800
19:51768638:GTTTC:G	acceptor_loss	0.9800
19:51768639:TTTCA:T	acceptor_loss	0.9800
19:51768640:TTCAG:T	acceptor_loss	0.9800
19:51768641:TCAGG:T	acceptor_loss	0.9800
19:51768642:CAGGT:C	acceptor_loss	0.9800
19:51768643:A:AG	acceptor_gain	0.9800
19:51768643:A:T	acceptor_loss	0.9800
19:51768644:G:GG	acceptor_gain	0.9800
19:51761228:CTGG:C	donor_loss	0.9700
19:51761229:TGG:T	donor_loss	0.9700
19:51761230:GGTAA:G	donor_loss	0.9700
19:51761231:G:GG	donor_gain	0.9700
19:51761231:GTAAG:G	donor_loss	0.9700
19:51761232:T:A	donor_loss	0.9700
19:51768644:GGT:G	acceptor_gain	0.9700
19:51761228:CTG:C	donor_gain	0.9300
19:51763488:GTCA:G	donor_gain	0.9300
19:51763489:TCAT:T	donor_gain	0.9300
19:51761011:TG:T	donor_gain	0.9200
19:51761226:TGCTG:T	donor_gain	0.9100
19:51761227:GCTGG:G	donor_gain	0.9100
19:51761212:A:T	donor_gain	0.8900
19:51761233:AA:A	donor_loss	0.8900
19:51768637:T:TA	acceptor_gain	0.8800
19:51761229:TG:T	donor_gain	0.8700
19:51761230:GG:G	donor_gain	0.8700
19:51761013:AAG:A	donor_gain	0.8600
19:51767350:C:T	donor_gain	0.8100

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000288991 (19:51767826 G>A,T), RS1000301661 (19:51761236 T>C,G), RS1000806940 (19:51768099 T>G), RS1000822672 (19:51764003 C>T), RS1001178751 (19:51760241 T>C), RS1001295458 (19:51760528 T>C), RS1001628880 (19:51761829 G>A), RS1001664588 (19:51764980 C>T), RS1001741533 (19:51762223 T>C), RS1001820156 (19:51765560 G>A), RS1001968450 (19:51768519 G>T), RS1002123165 (19:51768302 C>A,T), RS1002301745 (19:51761683 C>T), RS1002571711 (19:51769976 G>A), RS1002631542 (19:51763146 A>G,T)

Disease associations

OMIM: gene MIM:136538 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): primary ovarian failure (MONDO:0005387), lung adenocarcinoma (MONDO:0005061)

Orphanet (2): NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619), NON RARE IN EUROPE: Adenocarcinoma of the lung (Orphanet:415268)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

4 associations (top):

Study	Trait	p-value
GCST004866_7	Alopecia areata	6.000000e-06
GCST005531_84	Multiple sclerosis	3.000000e-06
GCST007277_24	Tourette syndrome	9.000000e-07
GCST009597_232	Multiple sclerosis	2.000000e-06

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3038479 (PROTEIN FAMILY), CHEMBL4227 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

4 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 79,620 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1707	LOPERAMIDE HYDROCHLORIDE	4	59,532
CHEMBL422	TRIFLUOPERAZINE	4	20,044
CHEMBL6056273	IDREBORMILAST	2	19
CHEMBL4784510	BMS-986235	1	25

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — Formylpeptide receptors

Most potent curated ligand interactions (40 total), top 25:

Ligand	Action	Affinity	Parameter
LXA4	Full agonist	12.0	pEC50
resolvin D1	Full agonist	11.9	pEC50
RvD1-ME	Full agonist	11.43	pEC50
aspirin-triggered resolvin D1	Full agonist	11.1	pEC50
WKYMVm	Full agonist	10.13	pKd
MHC binding peptide	Full agonist	10.0	pIC50
BMS-986331	Agonist	9.3	pEC50
[3H]LXA4	Full agonist	9.3	pKd
sCKβ8-1	Full agonist	9.13	pEC50
MMK-1	Full agonist	8.7	pEC50
PSMα3	Full agonist	8.67	pEC50
ACT-389949	Agonist	8.52	pEC50
humanin	Full agonist	8.46	pEC50
BMS-986235	Agonist	8.3	pEC50
fMet-Met-Tyr-Ala-Leu-Phe	Full agonist	7.82	pEC50
SHAAGtide	Full agonist	7.72	pEC50
compound 43 [PMID: 21173551]	Full agonist	7.4	pEC50
T21/DP107	Full agonist	7.3	pEC50
compound 1754-31 [PMID: 23788657]	Antagonist	7.09	pIC50
uPar fragment	Full agonist	7.08	pEC50
PBP10	Antagonist	7.0	pIC50
amyloid β	Full agonist	7.0	pEC50
CRAMP	Full agonist	7.0	pEC50
CGEN-855A	Full agonist	6.72	pIC50
fMet-Ile-Val-Thr-Leu-Phe	Full agonist	6.7	pEC50

Binding affinities (BindingDB)

344 measured of 687 human assays (700 total across all organisms); most potent 50 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
MLS000079917	EC50	0.0133 nM
2-(3-chlorophenyl)-4-N-methyltriazole-4,5-diamine	EC50	0.325 nM
3-[(4- iodophenyl)carbamoyl] spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-2-carboxylic acid	EC50	0.6 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
4-chloro-N-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-1-[4-methoxy-6-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptan-2-yl]-2-pyridinyl]-2-oxopyrrolidin-3-yl]benzamide	EC50	0.6 nM	US-20230348426: OXOPYRROLIDINE FPR2 AGONISTS
1-(4-bromophenyl)-3-{4-[2-(2- hydroxyphenyl)ethyl]-4- methyl-2,5-dioxoimidazolidin- 1-yl}urea	EC50	0.97 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- 4-methylpentanoyl]amino} pentanoic acid	EC50	1 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
3-({[-{[(4-bromo-2- fluorophenyl)carbamoyl]amino}- 2,5-dioxo-4-(propan-2- yl)imidazolidin-4- yl]acetyl}amino)propanoic acid	EC50	1 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-N-(2-amino-2-oxoethyl)- 2-{[(4- bromophenyl)carbamoyl]amino}- 4-methylpentanamide	EC50	1.1 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
{[2-{[(4- bromophenyl)carbamoyl] amino}-3-(1H-indol-3- yl)propanoyl]amino}acetic acid	EC50	1.4 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
3-[(4- iodophenyl)carbamoyl] spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-5-ene-2- carboxylic acid	EC50	1.6 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
N-(4-iodophenyl) spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-5-ene-2,3- dicarboxamide	EC50	1.6 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
3-[(4- iodophenyl)carbamoyl]-7,7- dimethylbicyclo[2.2.1]heptane- 2-carboxylic acid	EC50	1.7 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- 4-methylpentanoyl]amino}-3- methylbutanoic acid	EC50	1.7 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- N-[2-(dimethylamino)-2- oxoethyl]-4- methylpentanamide	EC50	1.7 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
{[(2S)-4-methyl-2-({[4- (trifluoromethyl)phenyl] carbamoyl}amino)pentanoyl] amino}acetic acid	EC50	1.8 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
N-(4-iodophenyl) spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-2,3- dicarboxamide	EC50	1.9 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
{[(2S)-2-{[(4- bromophenyl)carbamoyl] amino}4- methylpentanoyl]amino} methanesulfonic acid	EC50	2 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromophenyl)-3-{4-[2-(3- hydroxyphenyl)ethyl]-4- methyl-2,5-dioxoimidazolidin- 1-yl}urea	EC50	2.1 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromo-2-fluorophenyl)- 3-{4-[2-(3- hydroxyphenyl)ethyl]-4- methyl-2,5-dioxoimidazolidin- 1-yl}urea	EC50	2.2 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- 4-methyl-N-(1H-tetrazol- 5-ylmethyl)pentanamide	EC50	2.3 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-[2-(3-aminopropyl)-3-(4- cyanophenyl)-1-oxo-1,2,3,4- tetrahydroisoquinolin-7-yl]-3- [4-(methylsulfanyl)phenyl]urea	EC50	2.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
N-(4-bromophenyl) spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-2,3- dicarboxamide	EC50	2.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-N-(2-amino-2-oxoethyl)- 2-{[(4- bromophenyl)carbamoyl]amino} pentanamide	EC50	2.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- N-(2-hydroxy-2- methylpropyl)-4- methylpentanamide	EC50	2.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
2-methyl-2-{[(2S)-4-methyl-2-({[4- (trifluoromethyl)phenyl]carbamoyl} amino)pentanoyl]amino} propanoic acid	EC50	2.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
N-(4-iodophenyl)-7,7- dimethylbicyclo[2.2.1]heptane- 2,3-dicarboxamide	EC50	2.6 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
2-[1-{[(4- bromophenyl)carbamoyl]amino}- 2,5-dioxo-4-(propan-2- yl)imidazolidin-4-yl]-N-(2- hydroxyethyl)acetamide	EC50	2.7 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
CHEMBL4747556	EC50	2.9 nM
(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- N-[(2R)-1- hydroxypropan-2-yl]-4- methylpentanamide	EC50	3 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2-{(1S)-2-Methyl-1- [({[4- (trifluoromethyl)phenyl] amino}carbonyl)amino] propyl}-1H-imidazol-1- yl)acetic acid	EC50	3 nM	US-10301269: Imidazole derivatives as formyl peptide receptor modulators
1-(4-bromophenyl)-3-[4- methyl-2,5-dioxo-4-(2- phenylethyl)imidazolidin-1- yl]urea	EC50	3.2 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromophenyl)-3-[4-ethyl- 2,5-dioxo-4-(propan-2- yl)imidazolidin-1-yl]urea	EC50	3.3 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromophenyl)-3-{4- methyl-4-[2-(5-methylfuran-2- yl)ethyl]-2,5- dioxoimidazolidin-1-yl}urea	EC50	3.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-4-methyl-N-(1H-tetrazol- 5-ylmethyl)-2-({[4- (trifluoromethyl)phenyl]carbamoyl} amino)pentanamide	EC50	3.7 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromophenyl)-3-[2,5- dioxo-4,4-di(propan-2- yl)imidazolidin-1-yl]urea	EC50	3.8 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
3-({[1-{[(4- bromophenyl)carbamoyl]amino}- 2,5-dioxo-4-(propan-2- yl)imidazolidin-4- yl]acetyl}amino)propanoic acid	EC50	3.9 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
3-[(4- bromophenyl)carbamoyl] spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-5-ene-2- carboxylic acid	EC50	4 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromo-2-fluorophenyl)- 3-{4-[2-(2- hydroxyphenyl)ethyl]-4- methyl-2,5-dioxoimidazolidin- 1-yl}urea	EC50	4 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(4- iodophenyl)carbamoyl]amino}- 4-methylpentanoic acid	EC50	4 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-[(1S)-1-(1H-imidazol- 2-yl)-2-methylpropyl]- 3-[4- (trifluoromethyl)phenyl] urea	EC50	4 nM	US-10301269: Imidazole derivatives as formyl peptide receptor modulators
rel-(2R,3S)-3-[(4- bromophenyl)carbamoyl]spiro [bicyclo[2.2.1]heptane-7,1’- cyclopropane]-2-carboxylic acid	EC50	4 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-N-(2-amino-2-oxoethyl)- 2-{[(4-bromo-2- fluorophenyl)carbamoyl]amino}- 4-methylpentanamide	EC50	4.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S,3S)-N-(2-amino-2- oxoethyl)-2-{[(4- bromophenyl)carbamoyl]amino}- 3-methylpentanamide	EC50	4.6 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(4- bromophenyl)carbamoyl]amino}- 4-methyl-N-(2- oxopropyl)pentanamide	EC50	4.7 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
N-(4-bromophenyl) spiro[bicyclo[2.2.1]heptane- 7,1’-cyclopropane]-5-ene-2,3- dicarboxamide	EC50	4.8 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-2-{[(4- bromophenyl)carbamoyl] amino}-N-(2,3-dihydroxypropyl)- 4-methylpentanamide	EC50	5.1 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-(4-bromophenyl)-3-{4-[2- (furan-2-yl)ethyl]-4-methyl- 2,5-dioxoimidazolidin-1- yl}urea	EC50	5.2 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-N-(2-amino-2-oxoethyl)- 2-{[(4-bromo-2- fluorophenyl)carbamoyl]amino} pentanamide	EC50	5.2 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
1-{3-(4-cyanophenyl)-2-[2- (1H-imidazol-4-yl)ethyl]-1- oxo-1,2,3,4- tetrahydroisoquinolin-7-yl}-3- [4-(methylsulfanyl)phenyl]urea	EC50	5.5 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases
(2S)-N-[(2S)-1-amino-3- methyl-1-oxobutan-2-yl]-2- {[(4- bromophenyl)carbamoyl]amino}- 4-methylpentanamide	EC50	5.8 nM	US-10434112: Use of agonists of formyl peptide receptor 2 for treating dermatological diseases

ChEMBL bioactivities

2892 potent at pChembl≥5 of 2991 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
11.00	EC50	0.01	nM	CHEMBL5556956
10.70	EC50	0.02	nM	CHEMBL5271637
10.30	EC50	0.05	nM	CHEMBL4776349
10.30	IC50	0.05	nM	CHEMBL5268572
10.15	EC50	0.07	nM	CHEMBL3730217
10.15	EC50	0.07	nM	CHEMBL552527
10.15	EC50	0.07	nM	CHEMBL5567819
10.11	EC50	0.078	nM	CHEMBL4790836
10.11	EC50	0.077	nM	CHEMBL5542293
10.07	EC50	0.085	nM	CHEMBL4743917
10.06	EC50	0.087	nM	CHEMBL4755590
10.05	EC50	0.09	nM	CHEMBL5558065
10.04	EC50	0.092	nM	CHEMBL4744094
10.00	EC50	0.1	nM	CHEMBL3728769
10.00	IC50	0.1	nM	CHEMBL4440913
10.00	EC50	0.1	nM	CHEMBL6168024
10.00	EC50	0.1	nM	CHEMBL6171866
9.96	EC50	0.11	nM	CHEMBL4784400
9.96	EC50	0.11	nM	CHEMBL4758920
9.92	IC50	0.12	nM	CHEMBL5268572
9.89	EC50	0.13	nM	CHEMBL3729012
9.89	EC50	0.13	nM	CHEMBL5288361
9.89	EC50	0.13	nM	CHEMBL5550062
9.85	EC50	0.14	nM	CHEMBL4781596
9.85	EC50	0.14	nM	CHEMBL5284349
9.85	EC50	0.14	nM	CHEMBL5612530
9.85	EC50	0.14	nM	CHEMBL6160913
9.82	EC50	0.15	nM	CHEMBL4744835
9.82	EC50	0.15	nM	CHEMBL5284349
9.80	EC50	0.16	nM	CHEMBL3727613
9.80	EC50	0.16	nM	CHEMBL4762030
9.77	EC50	0.17	nM	CHEMBL5281870
9.77	EC50	0.17	nM	CHEMBL6028833
9.77	EC50	0.17	nM	CHEMBL6001886
9.74	EC50	0.18	nM	CHEMBL4744094
9.74	EC50	0.18	nM	CHEMBL5564103
9.72	EC50	0.19	nM	CHEMBL4761554
9.72	EC50	0.19	nM	CHEMBL6173514
9.70	EC50	0.2	nM	CHEMBL3728932
9.70	EC50	0.2	nM	CHEMBL5614343
9.70	EC50	0.2	nM	CHEMBL5550062
9.68	EC50	0.21	nM	CHEMBL5270733
9.68	EC50	0.21	nM	CHEMBL6159963
9.66	EC50	0.22	nM	CHEMBL5923729
9.66	IC50	0.22	nM	CHEMBL5268572
9.64	EC50	0.23	nM	CHEMBL6172222
9.62	EC50	0.24	nM	CHEMBL3729214
9.62	IC50	0.24	nM	CHEMBL5289939
9.60	EC50	0.25	nM	CHEMBL4794375
9.60	EC50	0.25	nM	CHEMBL5287715

PubChem BioAssay actives

711 with measured affinity, of 1689 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
1-(4-chlorophenyl)-3-[(3S,4R)-1-(2-hydroxyethyl)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	<0.0001	uM
1-[(7R,8S)-7-(2,6-difluoro-4-methoxyphenyl)-4,6,7,8-tetrahydro-3H-pyrrolo[2,1-c][1,2,4]oxadiazin-8-yl]-3-(4-fluorophenyl)urea	1932218: Agonist activity at FPR2 (unknown origin) assessed as increase in calcium flux	ec50	<0.0001	uM
1-(4-chloro-3-hydroxyphenyl)-3-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-(4-chlorophenyl)-3-[(3S,4R)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-(4-fluorophenyl)-3-[(3S,4R)-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-[(3S,4R)-4-(2,5-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-[(3S,4R)-1-ethyl-4-(4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea	1932219: Agonist activity at human FPR2 expressed in HEK293 cells assessed as increase in calcium flux incubated for 45 mins by Fluo-4 AM dye based fluorescence assay	ec50	0.0001	uM
1-(4-chlorophenyl)-3-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluoro-3-hydroxyphenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(3-hydroxy-4-methylphenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea	2127414: Agonist activity at human FPR2 expressed in CHO cells assessed as forskolin -induced cAMP level incubated for 30 mins in presence of IBMX by HTRF HiRange cAMP assay	ec50	0.0001	uM
1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0001	uM
1-(4-chlorophenyl)-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea	1932216: Agonist activity at human FPR2 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assay	ec50	0.0001	uM
methyl (E,5S,6R)-5,6-dihydroxy-8-[5-[(1S)-1-hydroxyhexyl]-1,2-dimethylimidazol-4-yl]oct-7-enoate	1585249: Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in IL-12p70 secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemiluminescence assay	ic50	0.0001	uM
1-(4-chlorophenyl)-3-[(3S,4S)-4-(4-methoxyphenyl)-2-oxopiperidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0001	uM
1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-(2-dimethylphosphoryl-3-fluorophenyl)-2,3-difluorophenyl]-2-oxopyrrolidin-3-yl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0001	uM
1-(4-chlorophenyl)-3-[(3S,4S)-3-(4-methoxyphenyl)-1-[(1-methylsulfonylpyrazol-4-yl)methyl]piperidin-4-yl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0001	uM
(2R,3R)-3-N-(4-bromophenyl)-2-N-(4-piperidin-1-ylbutyl)spiro[bicyclo[2.2.1]heptane-7,1’-cyclopropane]-2,3-dicarboxamide	2083663: Agonist activity at FPR2 (unknown origin) in HEK293 cells	ec50	0.0001	uM
(2S)-6-amino-2-[[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-amino-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methylsulfanyl-1-oxobutan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]hexanamide	2083635: Agonist activity at human FPR2	ec50	0.0001	uM
1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(3,4-difluorophenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0002	uM
1-[(3R)-1-[4-[1-(methanesulfonamidomethyl)cyclopropyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea	1932216: Agonist activity at human FPR2 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assay	ec50	0.0002	uM
1-[(3R)-1-[4-[3-(dimethylamino)piperidin-1-yl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0002	uM
1-(4-bromophenyl)-3-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0002	uM
1-(4-chlorophenyl)-3-[(1S)-1-[5-(2-hydroxyethyl)-1,2,4-oxadiazol-3-yl]-2-(4-methoxyphenyl)ethyl]urea	1932219: Agonist activity at human FPR2 expressed in HEK293 cells assessed as increase in calcium flux incubated for 45 mins by Fluo-4 AM dye based fluorescence assay	ec50	0.0002	uM
1-[(3R)-1-[4-[2-[methyl(methylsulfonyl)amino]phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea	2127414: Agonist activity at human FPR2 expressed in CHO cells assessed as forskolin -induced cAMP level incubated for 30 mins in presence of IBMX by HTRF HiRange cAMP assay	ec50	0.0002	uM
1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(3-methyl-1,2-thiazol-5-yl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0003	uM
1-(5-chlorothiophen-2-yl)-3-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0003	uM
1-(4-chlorophenyl)-3-[(1S)-1-[2-(2-hydroxyethyl)tetrazol-5-yl]-2-(4-methoxyphenyl)ethyl]urea	1932219: Agonist activity at human FPR2 expressed in HEK293 cells assessed as increase in calcium flux incubated for 45 mins by Fluo-4 AM dye based fluorescence assay	ec50	0.0003	uM
1-(4-fluorophenyl)-3-[(7R,8S)-7-(4-methoxyphenyl)-4-oxo-7,8-dihydro-6H-pyrrolo[2,1-c][1,2,4]oxadiazin-8-yl]urea	1932218: Agonist activity at FPR2 (unknown origin) assessed as increase in calcium flux	ec50	0.0003	uM
1-(4-fluorophenyl)-3-[(3R,4S)-4-(4-methoxyphenyl)oxolan-3-yl]urea	1731419: Agonist activity at FPR2 (unknown origin) by calcium mobilization assay	ec50	0.0003	uM
1-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-(4-methoxyphenyl)urea	2127414: Agonist activity at human FPR2 expressed in CHO cells assessed as forskolin -induced cAMP level incubated for 30 mins in presence of IBMX by HTRF HiRange cAMP assay	ec50	0.0003	uM
1-[(3R,4S)-3-(2,6-difluoro-4-methoxyphenyl)-5-(2-hydroxyethoxyamino)-3,4-dihydro-2H-pyrrol-4-yl]-3-(4-methoxyphenyl)urea	1932219: Agonist activity at human FPR2 expressed in HEK293 cells assessed as increase in calcium flux incubated for 45 mins by Fluo-4 AM dye based fluorescence assay	ec50	0.0003	uM
1-(4-chlorophenyl)-3-[(3R,4S)-4-(4-methoxyphenyl)-2-oxooxolan-3-yl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0003	uM
(2-methylphenyl)methyl N-[2-(5-oxohexyl)-1,3-oxazol-4-yl]carbamate	2083663: Agonist activity at FPR2 (unknown origin) in HEK293 cells	ec50	0.0003	uM
1-[(3S,4R)-4-(3-fluoro-5-methoxy-2-pyridinyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0004	uM
1-[(3S,4R)-4-(2,6-difluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-phenylurea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0004	uM
1-[(3S,4R)-4-(2-fluoro-4-methoxyphenyl)-2-oxopyrrolidin-3-yl]-3-(4-fluorophenyl)urea	1720303: Agonist activity at human FPR2 expressed in HEK 293 cells co-expressing Galpha15 measured every 1.5 sec for 80 sec by Fluo-4 NW staining based scanning fluorometric method	ec50	0.0004	uM
2-piperidin-4-ylethyl (2R,3R)-3-[(6-bromo-3-pyridinyl)carbamoyl]spiro[bicyclo[2.2.1]heptane-7,1’-cyclopropane]-2-carboxylate	2083663: Agonist activity at FPR2 (unknown origin) in HEK293 cells	ec50	0.0004	uM
1-[(3R)-1-[2,3-difluoro-4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea	2127414: Agonist activity at human FPR2 expressed in CHO cells assessed as forskolin -induced cAMP level incubated for 30 mins in presence of IBMX by HTRF HiRange cAMP assay	ec50	0.0004	uM
1-[(3R)-1-[4-[2-(tert-butylsulfamoyl)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-[4-(trifluoromethyl)phenyl]urea	2127414: Agonist activity at human FPR2 expressed in CHO cells assessed as forskolin -induced cAMP level incubated for 30 mins in presence of IBMX by HTRF HiRange cAMP assay	ec50	0.0005	uM
1-[(3R)-1-[4-[2-(tert-butylsulfamoyl)phenyl]phenyl]-2-oxopiperidin-3-yl]-3-(4-chlorophenyl)urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0005	uM
1-(4-chloro-2-fluorophenyl)-3-[(3R)-1-[4-(2-dimethylphosphorylphenyl)-2,3-difluorophenyl]-2-oxopyrrolidin-3-yl]urea	2083657: Agonist activity at FPR2 (unknown origin) expressed in CHO cells by cAMP assay	ec50	0.0005	uM
1-(4-chloro-2-fluorophenyl)-3-[(7R)-5-[4-(2-dimethylphosphorylphenyl)-2,3-difluorophenyl]-6-oxo-5-azaspiro[2.4]heptan-7-yl]urea	1932216: Agonist activity at human FPR2 expressed in CHO cells assessed as cAMP level incubated for 1.5 hr by HTRF assay	ec50	0.0005	uM
methyl (E,5S,6R)-5,6-dihydroxy-8-[5-[(1R)-1-hydroxyhexyl]-2,3-diphenylimidazol-4-yl]oct-7-enoate	1585252: Agonist activity at ALX/FPR2 in human THP1 cells harboring NF-kB-Luc assessed as inhibition of LPS-induced NFkB signalling activation by measuring reduction in IL-6 secretion pretreated for 30 mins followed by LPS stimulation for 24 hrs by electrochemiluminescence assay	ic50	0.0005	uM
1-(4-bromophenyl)-3-[4-ethyl-2,5-dioxo-4-(2-phenylethyl)imidazolidin-1-yl]urea	2083637: Agonist activity at human FPR2 expressed in HL-60 cells assessed as inhibition of WKYMVM-induced calcium mobilization	ec50	0.0005	uM
N-(4-bromophenyl)-2-(4-ethyl-2,5-dioxo-4-propan-2-ylimidazolidin-1-yl)acetamide	2083649: Agonist activity at human FPR2 expressed in CHO cells assessed as increase in calcium mobilization by Fluo-4 AM dye based fluorescence assay	ec50	0.0005	uM
1-(4-chlorophenyl)-3-[(1S)-2-(4-ethylphenyl)-1-[5-[2-hydroxyethyl(methyl)amino]-1,2,4-oxadiazol-3-yl]ethyl]urea	1932219: Agonist activity at human FPR2 expressed in HEK293 cells assessed as increase in calcium flux incubated for 45 mins by Fluo-4 AM dye based fluorescence assay	ec50	0.0006	uM
1-[(1Z,2S)-1-amino-3-(4-ethylphenyl)-1-(2-hydroxyethoxyimino)propan-2-yl]-3-(4-chlorophenyl)urea	1932219: Agonist activity at human FPR2 expressed in HEK293 cells assessed as increase in calcium flux incubated for 45 mins by Fluo-4 AM dye based fluorescence assay	ec50	0.0006	uM
1-[2-fluoro-4-(trifluoromethyl)phenyl]-3-[(3R)-1-[4-[2-(methanesulfonamido)phenyl]phenyl]-2-oxopiperidin-3-yl]urea	2127414: Agonist activity at human FPR2 expressed in CHO cells assessed as forskolin -induced cAMP level incubated for 30 mins in presence of IBMX by HTRF HiRange cAMP assay	ec50	0.0006	uM

CTD chemical–gene interactions

22 total (human), top 22 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
lipoxin A4	increases expression, affects binding, decreases activity, increases activity, increases abundance	2
Air Pollutants, Occupational	affects expression, decreases expression	2
triphenyl phosphate	affects expression	1
sulforaphane	increases expression	1
cobaltous chloride	increases expression	1
di-n-butylphosphoric acid	affects expression	1
CGP 52608	affects binding, increases reaction	1
nordy	decreases expression	1
gardiquimod	increases expression, decreases reaction	1
Arsenic	affects methylation	1
Aspirin	increases abundance, increases expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	increases expression	1
Methotrexate	decreases expression	1
Nickel	decreases expression	1
Quercetin	increases expression	1
Tetrachlorodibenzodioxin	decreases expression	1
Tretinoin	increases expression	1
Cyclosporine	increases methylation	1
Aflatoxin B1	increases methylation	1
Antirheumatic Agents	decreases expression	1
Protein Kinase Inhibitors	decreases reaction, increases expression	1

ChEMBL screening assays

194 unique, capped per target: 110 binding, 84 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL2342907	Binding	Agonist activity at FPR1/FPR2 receptor in human neutrophils assessed as stimulation of fMLP-OMe-induced superoxide radical generation at 0.1 uM incubated for 5 mins followed by fMLP-OMe induction by spectrophotometric analysis relative to c	A formyl peptide substituted with a conformationally constrained phenylalanine residue evokes a selective immune response in human neutrophils. — Bioorg Med Chem
CHEMBL2342908	Functional	Agonist activity at FPR1/FPR2 receptor in human neutrophils assessed as increase in intracellular calcium concentration by spectrofluorophotometric analysis	A formyl peptide substituted with a conformationally constrained phenylalanine residue evokes a selective immune response in human neutrophils. — Bioorg Med Chem

Cellosaurus cell lines

7 cell lines: 4 spontaneously immortalized cell line, 3 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_A6US	NP-2/CD4/FPRL1	Cancer cell line	Male
CVCL_F1U0	HyCyte THP-1 KO-hFPR2	Cancer cell line	Male
CVCL_H432	CHO-K1/FPRL1/Galpha15	Spontaneously immortalized cell line	Female
CVCL_KV17	cAMP Hunter CHO-K1 FPRL1 Gi	Spontaneously immortalized cell line	Female
CVCL_KX06	PathHunter CHO-K1 FPRL1 beta-arrestin	Spontaneously immortalized cell line	Female
CVCL_LA32	PathHunter U2OS FPRL1 Activated GPCR Internalization	Cancer cell line	Female
CVCL_ZK57	GeneBLAzer FPRL-1-Galpha15-NFAT-bla CHO-K1	Spontaneously immortalized cell line	Female

Clinical trials (associated diseases)

289 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00417066	PHASE4	COMPLETED	Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
NCT00732693	PHASE4	COMPLETED	Evaluation of Physiologic and Standard Sex Steroid Replacement Regimens in Women With Premature Ovarian Failure
NCT00837616	PHASE4	COMPLETED	Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
NCT01853501	PHASE4	UNKNOWN	Effects of ADSC Therapy in Women With POF
NCT02783937	PHASE4	COMPLETED	Filgrastim for Premature Ovarian Insufficiency
NCT03535480	PHASE4	UNKNOWN	Autologous Bone Marrow Stem Cell Ovarian Transplantation to Restore Ovarian Function in Premature Ovarian Failure
NCT02399566	PHASE4	UNKNOWN	Clinical Trial of Erlotinib and Pemetrexed for Maintenance Treatment in Lung Adenocarcinoma
NCT02804646	PHASE4	UNKNOWN	Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma
NCT00140998	PHASE3	COMPLETED	Estrogen Treatment (Oral vs. Patches) in Turner Syndrome
NCT00002852	PHASE3	COMPLETED	Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer
NCT00005838	PHASE3	COMPLETED	Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00020709	PHASE3	COMPLETED	Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
NCT00049543	PHASE3	COMPLETED	Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery
NCT00946712	PHASE3	TERMINATED	S0819: Carboplatin and Paclitaxel With or Without Bevacizumab and/or Cetuximab in Treating Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer
NCT01798485	PHASE3	TERMINATED	A Phase 3 Study of Ganetespib in Combination With Docetaxel Versus Docetaxel Alone in Patients With Advanced NSCLC
NCT02011997	PHASE3	UNKNOWN	Comparison of cVATS Segmentectomy Versus Lobectomy for Lung Adenocarcinoma in Situ and With Microinvasion
NCT03391869	PHASE3	ACTIVE_NOT_RECRUITING	Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer
NCT03676192	PHASE3	COMPLETED	To Compare Efficacy and Safety of CT-P16 and European Union-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer
NCT04339218	PHASE3	RECRUITING	Cryoablation in Combination (or Not) With Pembrolizumab and Pemetrexed-carboplatin in 1st-line Treatment for Patients With Metastatic Lung Adenocarcinoma
NCT05204758	PHASE3	COMPLETED	Prophylactic TCM for Mitigation of EGFR-TKI Related Dermatological Adverse Effect
NCT05717803	PHASE3	RECRUITING	Segmentectomy for Ground Glass-dominant Invasive Lung Cancer (ECTOP-1012)
NCT05943795	PHASE3	ACTIVE_NOT_RECRUITING	A Clinical Study of SI-B001 Combined With Docetaxel in the Treatment of Non-small Cell Lung Adenocarcinoma and Lung Squamous Cell Carcinoma
NCT06031181	PHASE3	RECRUITING	Sublobar Resection for Adenocarcinoma in Situ/Minimally Invasive Adenocarcinoma Diagnosed by Intraoperative Frozen Section (ECTOP-1019)
NCT06031246	PHASE3	RECRUITING	Selective Lymph Node Dissection for cT1N0M0 Invasive NSCLC With CTR>0.5 Located in the Apical Segment (ECTOP-1018)
NCT06634966	PHASE3	RECRUITING	Segmentectomy for Solid-dominant Lung Cancer
NCT07169903	PHASE3	NOT_YET_RECRUITING	Segmentectomy vs Lobectomy for 2 - 3cm IASLC Grade 1-2 Lung Adenocarcinoma: A Multi-center RCT
NCT07481786	PHASE3	RECRUITING	Bevacizumab Plus FSRT Versus Hippocampus-Avoidant WBRT in Lung Adenocarcinoma With Extensive Brain Metastases
NCT00001951	PHASE2	COMPLETED	Hormone Replacement in Young Women With Premature Ovarian Failure
NCT00370019	PHASE2	WITHDRAWN	Effects of an Estrogen Replacement Therapy Skin Patch on Ovulation in Women With Premature Ovarian Failure
NCT00429494	PHASE2	COMPLETED	GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
NCT03816852	PHASE2	SUSPENDED	The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
NCT04536467	PHASE2	UNKNOWN	Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT06117982	PHASE2	COMPLETED	The Impact of Granulocyte Colony Stimulating Factor on Premature Ovarian Insufficiency
NCT00040794	PHASE2	COMPLETED	Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer
NCT00087412	PHASE2	COMPLETED	S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer
NCT00118144	PHASE2	COMPLETED	Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer
NCT00118183	PHASE2	COMPLETED	Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer
NCT00126581	PHASE2	COMPLETED	Erlotinib Hydrochloride With or Without Carboplatin and Paclitaxel in Treating Patients With Stage III-IV Non-small Cell Lung Cancer
NCT00334815	PHASE2	ACTIVE_NOT_RECRUITING	Combination Chemotherapy, Radiation Therapy, and Bevacizumab in Treating Patients With Newly Diagnosed Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
NCT00368992	PHASE2	COMPLETED	S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer